Exagen Inc. (FRA:E08A)

Market Cap	70.20M +31.3%
Revenue (ttm)	54.21M +14.1%
Net Income	-16.23M
EPS	-0.80
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	45
Open	3.660
Previous Close	3.820
Day's Range	3.660 - 3.660
52-Week Range	2.560 - 10.200
Beta	n/a
RSI	20.14
Earnings Date	Mar 16, 2026

About Exagen

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and ot...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2002
• Employees: 215
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E08A

Financial Performance

In 2024, Exagen's revenue was $55.64 million, an increase of 5.89% compared to the previous year's $52.55 million. Losses were -$15.12 million, -36.19% less than in 2023.

Financial numbers in USD